Search
Levacetylmethadol
go.drugbank.com/drugs/DB01227ApprovedWithdrawnLevacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well.[L44052,T862]
Tocilizumab
go.drugbank.com/drugs/DB06273ApprovedInvestigational[L12789] It was later approved by Health Canada on 30 April 2010. … [L44483] Tocilizumab-bavi, a biosimilar drug, was approved by the FDA in September 2023.[L48385].
Tegoprazan
go.drugbank.com/drugs/DB16690InvestigationalTegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases. … [A234215, A234220] Tegoprazan’s strong and sustained effect is due to its ability to be slowly cleared from the gastric glands and exertion of effects independent of acid levels.
Olsalazine
go.drugbank.com/drugs/DB01250Approved[A257078] Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. … [A257078] Olsalazine is an anti-inflammatory agent that works by inhibiting cyclooxygenase and lipoxygenase, subsequently reducing the production of pro-inflammatory factors like prostaglandin and leukotriene
Sparteine
go.drugbank.com/drugs/DB06727ApprovedWithdrawnSparteine is a plant alkaloid derived from _Cytisus scoparius_ and _Lupinus mutabilis_ which may chelate calcium and magnesium. … Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness
Dasatinib
go.drugbank.com/drugs/DB01254ApprovedInvestigational[A2226] The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186]
Synonyms: N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamideSaxagliptin
go.drugbank.com/drugs/DB06335ApprovedInvestigationalSaxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
go.drugbank.com/drugs/DB10342ApprovedInvestigationalHaemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen is a vaccine containing outer membrane antigen extracted from *Haemophilus influenzae*.
Daratumumab
go.drugbank.com/drugs/DB09331ApprovedInvestigationalDaratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. … This approval was based on results from the Phase 3 PERSEUS study, which demonstrated significant improvement in progression-free survival and higher rates of minimal residual disease (MRD) negativity
Danicopan
go.drugbank.com/drugs/DB15401ApprovedInvestigational[A263506] It was subsequently approved by the FDA in March 2024.[L50386] … Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis, thrombophilia, and bone marrow dysfunction.
Synonyms: (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide, (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamide